These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536 [TBL] [Abstract][Full Text] [Related]
9. Meclizine and Metabotropic Glutamate Receptor Agonists Attenuate Severe Pain and Ca Shannonhouse J; Bernabucci M; Gomez R; Son H; Zhang Y; Ai CH; Ishida H; Kim YS J Neurosci; 2022 Aug; 42(31):6020-6037. PubMed ID: 35772967 [TBL] [Abstract][Full Text] [Related]
10. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711 [TBL] [Abstract][Full Text] [Related]
12. Positive allosteric modulation of the cannabinoid CB Green HM; Manning JJ; Greig IR; Ross RA; Finlay DB; Glass M Br J Pharmacol; 2024 Oct; 181(19):3642-3662. PubMed ID: 38831545 [TBL] [Abstract][Full Text] [Related]
13. CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain. Krukowski K; Eijkelkamp N; Laumet G; Hack CE; Li Y; Dougherty PM; Heijnen CJ; Kavelaars A J Neurosci; 2016 Oct; 36(43):11074-11083. PubMed ID: 27798187 [TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy. Vera G; Cabezos PA; Martín MI; Abalo R Pharmacol Biochem Behav; 2013 Apr; 105():205-12. PubMed ID: 23454533 [TBL] [Abstract][Full Text] [Related]
15. DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain. Li Y; North RY; Rhines LD; Tatsui CE; Rao G; Edwards DD; Cassidy RM; Harrison DS; Johansson CA; Zhang H; Dougherty PM J Neurosci; 2018 Jan; 38(5):1124-1136. PubMed ID: 29255002 [TBL] [Abstract][Full Text] [Related]
16. Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain. Wilkerson JL; Alberti LB; Kerwin AA; Ledent CA; Thakur GA; Makriyannis A; Milligan ED Brain Behav; 2020 Dec; 10(12):e01850. PubMed ID: 32977358 [TBL] [Abstract][Full Text] [Related]
17. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Sagar DR; Kelly S; Millns PJ; O'Shaughnessey CT; Kendall DA; Chapman V Eur J Neurosci; 2005 Jul; 22(2):371-9. PubMed ID: 16045490 [TBL] [Abstract][Full Text] [Related]
19. The Antinociceptive and Antiinflammatory Properties of 3-furan-2-yl-N-p-tolyl-acrylamide, a Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptors in Mice. Bagdas D; Targowska-Duda KM; López JJ; Perez EG; Arias HR; Damaj MI Anesth Analg; 2015 Nov; 121(5):1369-77. PubMed ID: 26280585 [TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of the CB Mustafa M; Donvito G; Moncayo L; Swafford A; Poklis J; Grauer R; Olszewska T; Ignatowska-Jankowska B; Kendall DA; Lu D; Lichtman AH Pharmacol Biochem Behav; 2020 Mar; 190():172840. PubMed ID: 31899221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]